Skip to content
value.today

Precision Therapeutics Inc.

Total raised
$48 M
2 rounds on record
Latest round
$14 M
Jul 2013
First round on record
May 2010
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Precision Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2013$14 MNo. 2$10 to $50 million

Precision Therapeutics Inc.: Raise no. 2, Jul 2013

Investors in this round

2 investors had bought by the notice of Aug 7, 2013: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$14 M of $21 M offered; $7 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Mike C. Gabrin · Executive Officer
  • Sean McDonald · Executive Officer, Director
  • Clarke B. Futch · Director
  • Matthew T. Reber · Director
  • Todd C. Davis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “$9,000,000 from the total amount sold was from Convertible Debt.”

Signed by Sean McDonald, President and CEO. Source: SEC Form D, newest notice filed Aug 7, 2013. Read the notice at the SEC.

equitySEC
May 2010$34 MNo. 1$10 to $50 million

Precision Therapeutics Inc.: Raise no. 1, May 2010

Investors in this round

45 investors had bought by the notice of Jun 4, 2010: 45 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$34 M of $35 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David R. Heilman · Executive Officer
  • Holly H. Gallion, M.D. · Executive Officer
  • Mike R. Gabrin · Executive Officer
  • Sean McDonald · Executive Officer, Director
  • Sharon H. Kim · Executive Officer
  • David P. Hirsch · Director
  • Jeff N. Crisan · Director
  • Joel P. Adams · Director
  • Kevin P. Johnson · Director
  • Richard S. Kollender · Director
  • Stanley N. Lapidus · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David R. Heilman, Chief Financial officer and Secretary. Source: SEC Form D, newest notice filed Jun 4, 2010. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Precision Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2013).

    SEC Form D · Aug 2013

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Aug 2013

That is all the official record says: Precision Therapeutics Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Precision Therapeutics Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 45 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Precision Therapeutics Inc.
NameRoleNamed in
Mike C. GabrinExecutive officerAug 2013
Sean McDonaldExecutive officerAug 2013
David R. HeilmanExecutive officerJun 2010
Holly H. Gallion, M.D.Executive officerJun 2010
Mike R. GabrinExecutive officerJun 2010
Sharon H. KimExecutive officerJun 2010
Clarke B. FutchDirectorAug 2013
Matthew T. ReberDirectorAug 2013
Sean McDonaldDirectorAug 2013
Todd C. DavisDirectorAug 2013
David P. HirschDirectorJun 2010
Jeff N. CrisanDirectorJun 2010
Joel P. AdamsDirectorJun 2010
Kevin P. JohnsonDirectorJun 2010
Richard S. KollenderDirectorJun 2010
Stanley N. LapidusDirectorJun 2010